Literature DB >> 10919661

Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.

S Sarkar1, K P Jülicher, M S Burger, V Della Valle, C J Larsen, T R Yeager, T B Grossman, R W Nickells, C Protzel, D F Jarrard, C A Reznikoff.   

Abstract

Inactivation of both the pRb (pRb-cyclin D1/cyclin-dependent kinase 4/6-p16) and p53 (p53-p21(WAF1)-p14(ARF)) pathways is thought to be essential for immortalization in vitro and malignant transformation in vivo. We identified different combinations of pRb and p53 pathway alterations in 12 invasive transitional cell carcinomas (TCCs) and addressed the functional significance of the different combinations observed. Results showed four combinations of alterations including -pRb/-p53 (ie., pRb inactivated in the pRb pathway and p53 inactivated in the p53 pathway; four TCCs), -p16/-p53 (four TCCs), -p16/-p21(WAF1) (one TCC), and -p16/ -p14(ARF) (two TCCs). These groups include two new combinations (ie., -p16/-p53 and -p16/-p21(WAF1)) not reported previously for TCCs. An alteration in the key components of the p53 pathway was not detected in one invasive TCC that had inactivated p16. Note that all four TCCs with inactivated pRb had mutant p53; thus, the combinations of -pRb/ -p21(WAF1) and -pRb/-p14(ARF) were not observed. Only two of eight TCCs with altered p16 had concomitant p14(ARF) loss, demonstrating that simultaneous inactivation of these two 9p21INK4a tumor suppressor genes is not obligatory. To determine the biological phenotypes of TCCs with different combinations of pRb and p53 pathway alterations, their downstream responses to gamma radiation were studied in vitro. As expected, none of eight TCCs with mutant p53 responded to gamma radiation by elevation of p53, p21(WAF1), or mdm2 or by cell cycle arrest. Only two of four TCCs with wild-type p53 and wild-type pRb (the combination of -p16/-p14(ARF)) showed normal downstream responses to gamma radiation and underwent cell cycle arrest. Two TCCs with wild-type pRb and wild-type p53 (the combination of -pl6/-p21(WAF1) and one TCC with -p16) failed to show cell cycle arrest in response to radiation. This was attributed to the absence of p21(WAF1) in one TCC. In summary, these data support a model of invasive bladder cancer pathogenesis in which both the pRb and p53 pathways are usually inactivated and the biology of the tumor is impacted by the mechanism of their inactivations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10919661

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.

Authors:  Yang Liu; David J Kwiatkowski
Journal:  Mol Cancer Ther       Date:  2014-10-27       Impact factor: 6.261

2.  The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis.

Authors:  K Evangelou; J Bartkova; A Kotsinas; I S Pateras; M Liontos; G Velimezi; M Kosar; T Liloglou; I P Trougakos; L Dyrskjot; C L Andersen; M Papaioannou; Y Drosos; G Papafotiou; Z Hodny; B Sosa-Pineda; X-R Wu; A Klinakis; T Ørntoft; J Lukas; J Bartek; V G Gorgoulis
Journal:  Cell Death Differ       Date:  2013-07-12       Impact factor: 15.828

3.  Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.

Authors:  Juan F García; Raquel Villuendas; Margarita Sánchez-Beato; Abel Sánchez-Aguilera; Lydia Sánchez; Ignacio Prieto; Miguel A Piris
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

Review 4.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

Review 5.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

6.  Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer.

Authors:  L E De Faveri; C D Hurst; F M Platt; C F Taylor; J-A Roulson; M Sanchez-Carbayo; M A Knowles; E J Chapman
Journal:  Br J Cancer       Date:  2013-04-02       Impact factor: 7.640

7.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

8.  FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms.

Authors:  Darren C Tomlinson; Euan W Baxter; Paul M Loadman; Mark A Hull; Margaret A Knowles
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

9.  Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

Authors:  D C Tomlinson; C D Hurst; M A Knowles
Journal:  Oncogene       Date:  2007-03-26       Impact factor: 9.867

10.  Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.

Authors:  Louis S Pymar; Fiona M Platt; Jon M Askham; Ewan E Morrison; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2008-04-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.